Acute kidney injury after cardiac surgery
Conditions
Interventions
Esketamine :Esketamine is continuously infused at 0.3 mg/kg/h until skin closure
Saline:Equal volume of normal saline, with the same infusion duration and rate as the experimental group.
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age = 18 years; 2. Elective cardiopulmonary bypass cardiac surgery; 3. AKI risk score = 4; 4. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Pre-existing AKI before surgery (Scr increase =26.5 µmol/L or urine output 180 mmHg and/or diastolic blood pressure >110 mmHg) or history of hypertensive crisis; 9. Severe coronary artery disease, unstable angina, myocardial infarction <3 months, NYHA Class III-IV cardiac function; 10. Increased intracranial pressure, intracranial tumor, aneurysm, epilepsy or history of epilepsy; 11. Active psychiatric disorders (schizophrenia, manic episode, major depression with suicidal tendency, etc.); 12. Uncontrolled hyperthyroidism; 13. Concurrent use of MAOIs, NMDA antagonists (such as amantadine, memantine) or psychoactive drugs; 14. History of severe drug abuse or dependence (opioids, benzodiazepines, cocaine, etc.); 15. Other conditions deemed by the investigator as unsuitable for esketamine use (such as severe sleep apnea, severe hypoxemia, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of acute kidney injury within 7 days postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| AKI stage distribution,;Peak Scr and change curve;Urine output indicators;Urinary kidney injury biomarker TIMP-2×IGFBP7;NETs biomarker MPO-DNA;Renal replacement therapy (RRT) requirement;Hospital resource utilization;90-day composite events; | — |
Countries
China
Contacts
Public ContactChanghong Miao
Zhongshan Hospital, Fudan University
Outcome results
None listed